Biogen Reports Q3 2026 Results, Raises EPS Guidance
Biogen reported adjusted Q3 2026 EPS of $2.62 and revenue of $2.80 billion, above FactSet consensus estimates of $1.99 and $2.63 billion, respectively. It raised the low end of its fiscal 2026 non-GAAP EPS guidance to $12.20, with a range of $12.20 to $13.00.
Biogen Inc. released its financial results for the third quarter of 2026, reporting adjusted earnings per share (EPS) of $2.62, which outperformed the FactSet analyst consensus of $1.99. The company also reported quarterly revenue of $2.80 billion, beating the consensus estimate of $2.63 billion. Additionally, Biogen updated its financial outlook, raising the low end of its fiscal year 2026 non-GAAP EPS guidance to a range of $12.20 to $13.00.
The company is increasingly focusing on newer drug assets to offset competitive pressures within its established multiple sclerosis franchise.